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Available online 4 November 2013The majority of patients diagnosed with neuroblastoma present with aggressive disease.
Improved detection of neuroblastoma cancer cells following initial therapy may help in
stratifying patient outcome and monitoring for relapse. To identify potential plasma
biomarkers, we utilised a liquid chromatography–tandem mass spectrometry-based proteo-
mics approach to detect differentially-expressed proteins in serum from TH-MYCN mice.
TH-MYCN mice carry multiple copies of the human MYCN oncogene in the germline and
homozygous mice for the transgene develop neuroblastoma in a manner resembling the
human disease. The abundance of plasma proteins was measured over the course of disease
initiation and progression. A list of 86 candidate plasma biomarkers was generated. Pathway
analysis identified significant association of these proteins with genes involved in the
complement system. One candidate, complement C3 protein, was significantly enriched in
the plasma of TH-MYCN+/+ mice at both 4 and 6 weeks of age, and was found to be elevated in a
cohort of human neuroblastomaplasma samples, compared to healthy subjects. In conclusion,
we have demonstrated the suitability of the TH-MYCN+/+ mouse model of neuroblastoma for
identification of novel disease biomarkers in humans, and have identified Complement C3 as a
candidate plasma biomarker for measuring disease state in neuroblastoma patients.
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2 J O U R N A L O F P R O T E O M I C S 9 6 ( 2 0 1 4 ) 1 – 1 2effectively allowed the identification of plasma proteins which may serve as potential
biomarkers of neuroblastoma. Furthermore, the label-free ion count quantitation technique
which was used displays significant benefits as it is less labour intensive, feasible and
accurate. We have been able to successfully validate this approach by confirming the
differential abundance of two different plasma proteins. In addition, we have been able to
confirm that the candidate biomarker Complement C3, is more abundant in the plasma of
human neuroblastoma patient plasma samples when compared to healthy counterparts.
Overall we have demonstrated that this approach can be potentially useful in the
identification of biomarker candidates, and that further validation of the candidates may
lead to the discovery of novel, clinically useful diagnostic tools in the detection of
sub-clinical neuroblastoma.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Neuroblastoma is an embryonal tumour of the sympatho-
adrenal tissues, and is one of the most common tumours in
early childhood [1]. More than half of children with neuroblas-
toma present clinically beyond 18 months of age with aggres-
sive disease resulting in high mortality rates. Most patients
enter clinical remission with intensive chemo-radiotherapy
and surgery, only to relapse later from a point of minimal
residual disease (MRD). Accurate detection of disease activity
following initial therapy, at a stage ofMRD,would better predict
relapse risk and aid in directing the choice of further treatment.
Furthermore, the identification of sensitive biomarkers may
offer thehope of a pre-clinical diagnosis strategy in infants prior
to the initial clinical presentation at an earlier disease stage.
mRNA expression levels of neuroblastoma-specific genes, such
as paired-like homeobox 2B (PHOX2B) and tyrosine hydroxylase
(TH), in circulating cells from blood samples taken during
therapy have been developed for the detection of MRD [2].
However, heterogeneous expression of these biomarkers in
tumour samples decreases the sensitivity of this strategy. Since
no sensitive plasma protein biomarkers are currently available
for risk estimation at diagnosis or during therapy, there is
immense clinical value for the identification of novel bio-
markers aimed at detection of neuroblastoma [3].
TheMYCN oncogene is amplified in tumour tissue from 20–
25% of children with neuroblastoma and predicts a poor
prognosis [4,5]. The TH-MYCN+/+ mice used as a neuroblastoma
disease model in this study express the human MYCN gene
under the control of a rat TH promoter in neuroectodermal cells
[6]. Large, paravertebral thoracic or abdominal tumours develop
in 100% of homozygous TH-MYCN+/+mice at 6 weeks of age and
33% in the hemizygous mice at 13 weeks of age [7]. Histologic,
immunohistochemical and cytogenetic studies have shown
that these tumours are indistinguishable from human neuro-
blastoma tissue [6]. Tumour formation in these mice follows
delayed and incomplete regression of neuroblast hyperplasia in
amanner representative of human childhood cancer initiation,
which is believed to develop as a consequence of abnormal
persistence of embryonal rest cells by largely unknown
mechanisms. Thismodel is ideal to use for the characterisation
of differences in protein profiles from plasma samples of
TH-MYCN+/+ and wild-type (WT) littermate mice, as they relate
to different stages of tumourigenesis.
Label-free mass spectrometry allows for the identification
and characterisation of individual proteins and peptideswithin complex biological samples using ion count or spectral
count techniques [8–10]. In combination with protein frac-
tionation techniques, such as in-solution electrophoresis, this
technique reduces the complexity of proteomic samples, and
allows for increased sensitivity which is particularly impor-
tant for detecting biologically significant proteins expressed
at low levels in plasma where the total concentration range
of proteins can exceed ten orders of magnitude [11]. Mass
spectrometry techniques have led to the characterisation of
several novel biomarkers which are currently being developed
for the diagnosis of bladder [12], ovarian [13] and lung cancers
[14]. The ion count label-free approach determines the
abundance of a ‘peptide’ based on the normalised ion count
of peptide features between sample groups, and has been
successfully used to identify deregulated and abnormally
expressed proteins in human disease [15,16].
In this study, plasma was harvested from TH-MYCN+/+ and
WT control mice at 2, 4, and 6 week time-points, representing
different stages in the initiation and progression of tumour-
igenesis. Using in-solution electrophoretic enrichment of the
lower mass component, liquid chromatography–tandem mass
spectrometry (LC–MS/MS) and label-free quantitation, approx-
imately 200 differentially abundant proteins from each time-
point were identified. The quantitative proteomics approach
was validated using 2D gel electrophoresis and ELISA, and
a final list of 86 protein candidates was generated which
demonstrated significant differential expression at more than
one time point. One candidate, Complement C3, was quantified
in the plasma of a cohort of human neuroblastoma patients at
diagnosis and found to be elevated compared to healthy
controls, suggesting that this protein should be further studied
as a plasma biomarker for assessing disease activity in neuro-
blastoma patients.2. Materials and methods
2.1. Sample collection
Blood from ten TH-MYCN+/+ transgenic and ten WT mice were
collected by cardiac puncture into vacutainers (5 ml EDTA
tubes with a purple top), from 2, 4 and 6 week old mice groups
(n = 60). Ethical approval for this study was obtained from the
Animal Care and Ethics Committee (Animal ethics approval
number 11/110A). Blood plasma was separated via centrifu-
gation (3000 g for 5 min) and stored at −80 °C for further use.
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matched WT and TH-MYCN+/+ mice respectively for later
analysis by ELISA. Upon dissection, the isolated tissue was
washed and cleaned of non-specific tissue in Hanks Balanced
Salt Solution and snap-frozen for storage. The sympathetic
ganglia (pooled superior cervical ganglia and coeliac ganglia)
were isolated from WT mice for comparison with early and
advanced-stage tumours from 4 week old and 6 week old
TH-MYCN+/+ mice respectively. For each age/genotype, ganglia
or tumours were isolated from 4 different mice and later
purified as protein lysates for ELISA.
Human plasma samples from healthy volunteers were
obtained from the Sydney Red Cross (N = 4) and Sydney Cord
Blood Bank (N = 3) under the ethics approval (#08/148) from the
South Eastern Sydney Illawarra. The samples obtained from the
Red Cross were from healthy adults and the samples from the
Cord Blood Bank were from healthy newborns. These samples
were used as a normal healthy control for this project. The
plasma samples fromneuroblastomapatientswere collectedby
DrNai-KongCheung from theMemorial Sloan-Kettering Cancer
Centre (NewYork, USA), under the clinical trial study,Molecular
Characterisation of Neuroblastic Tumour: Correlation with
Clinical Outcome (Clinical Trials identifier: NCT00588068) and
with the IRB protocol number #00–109. These samples were
from patients with MYCN-amplified tumours (n = 9), which
were all stage VI and MYCN-non-amplified tumours (n = 6),
where four of these were from stage I and one each from stages
II and III. The average age of the patients from which the
samples were collected from was 3.7 years and all of these
samples were collected at time of diagnosis.
2.2. Sample, fractionation, purification and analysis
by LC–MS/MS
Aliquots (200 μg plasma proteins for each sample) were
pooled and an appropriate volume of protease inhibitor was
added (Complete™, mini, EDTA-free, protease inhibitor tablet
from Roche Diagnostics, Manheim, Germany) as per manu-
facturer recommendations. An in-solution electrophoretic
device called ProteomeSep (NuSep, NSW, Australia) was used
to analyse the plasma from each genotype and each time-
point. Individual plasma samples were also stored for further
analysis with 2D gel electrophoresis and ELISA. The plasma
proteins were partitioned into five fractions based on protein
mass, pI and surface charge using the ProteomeSep, a
preparative electrophoresis instrument which causes charged
molecules to migrate across hydro gel membranes into dif-
ferent molecular weight fractions when a voltage is applied.
ProteomeSep fractionations were performed using 5-chamber
assembly, where chamber boundaries were defined by 2.7 ×
2.2 cm polyacrylamide membranes of different restrictive
pore sizes. All buffers described for sample preparations
were also used as circulating buffers. Plasma was diluted 1:1
to give a final concentration of 14 μg/ml plasma in 45 mM
Tris/5 mM ε-aminocaproic acid (EACA) buffer in 2 M urea,
pH 10.2. All fractionations were performed at 50 V for 30 min
and then 250 V for 2 h at 15 °C. The fractions were recovered
from the chambers using gel-loading tips. The fractions
collected were; 1–5 kDa, 5–25 kDa, 25–50 kDa, 50–75 kDa and
> 75 kDa. The two low molecular mass fractions, 1–5 kDa and5–25 kDa fractionswere desalted using C18 Stage Tips (Proxeon,
Odense, Denmark) as per manufacturer's instructions.
The peptides were resuspended in 5 μl of buffer A 2% (v/v)
acetic acid, 0.1% (v/v) FA and separated by nano-LC using
an Ultimate 3000 HPLC and autosampler system (Dionex,
Netherlands) and then concentrated and desalted onto amicro
C18 pre-column (500 μm × 2 mm, Michrom Bioresources, USA)
with 0.05% (v/v) heptafluorobutyric acid (HFBA) at 20 μl/min.
After a 4 min washing, the pre-column was automatically
switched (Valco 10 port valve, Houston, Texas, USA) into line
with a fritless nano column, as previously published [17]. The
LTQ-FT (Thermo Scientific, San Jose, CA, USA) was operated as
described previously [17]. Peak lists were generated using
‘Mascot Daemon/extract_msn’ (Matrix Science), default param-
eters and then submitted to the protein database search
programme Mascot (Matrix Science, Boston, USA).
2.3. Label-free quantification of identified peptides using
ion count
All LC–MS/MS spectra were searched against the mammalian
non-redundant NCBI database (2010) using Mascot (www.
matrixscience.com). In solution digests analysed on the
LTQ-FT Ultra were searched with the following criteria: trypsin
digestion, precursor and product ion tolerances ±6 ppm and
±0.6 Da, respectively; variable modifications of methionine
oxidation, phosphorylation (S, Y, T), carbamidomethyl and
acrylamide; and one missed cleavage allowed. Identifications
were accepted based on the MOWSE scores with a score > 44
indicating significant homology (p < 0.05).
Acquired spectra run in triplicate for each time point and in
each fraction files were loaded into the Progenesis LC–MS/MS
software (version 2.5, Nonlinear) for label-free quantification.
The datasets generated by the MS analysis of plasma proteins
from 2, 4 and 6 week old TH-MYCN+/+ and WT mice were
transformed into peak lists representing a 2D map using
retention time and m/z. Each size fraction from each time-point
was analysed separately and aligned according to retention time
to create a 2D LC feature map. Features selected for inclusion
were charge state inclusive ofMH2+ toMH3+, retention time from
13 min, and non-matching features were filtered out from
further analysis. The samples were then allocated to their
experimental group, including positive group (TH-MYCN+/+) and
negative group (WT). Statistical parameters (p < 0.05 and
fold-change > 5) were added to the sample analysis criteria to
identify significant differences in peptide quantification. Pep-
tides differing in either TH-MYCN+/+ or WT mice were followed
closely during the progression of disease. Parent ion information
that was used to quantitate the peptides, and then the daughter
ions were used to search Mascot, after which the identifications
imported and linked back to each parent ion “feature”.
2.4. Database search and protein identification
All LC–MS/MS spectra were searched using Mascot against the
mammalian non-redundant NCBI database with the following
criteria: the precursor tolerance and the product ion toler-
ances were at 6 ppm and ±0.6 Da respectively; variable
modification of methionine oxidation and trypsin digest.
Mascot generated Dat.files were also then accumulated in
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differential abundance based on ion counts.
2.5. Removal of plasma abundant proteins for validation
assays
Mouse abundant plasma proteins were depleted from each
sample using the ProteoSpinTM abundant plasma protein
depletion kit (Norgen Biotek Corp., Ontario, Canada), accord-
ing to the manufacturer's protocol.
Eluted protein samples were measured for protein concen-
tration using the BCA protein assay (Thermo Scientific) and
then stored at −20 °C for further downstream experiments.
2.6. Two dimensional analysis of protein candidates
Abundant protein depleted plasma samples from 6 week old
TH-MYCN+/+ transgenic and WT mice were separated and
analysed on 2D gels. IPG strips (11 cm, pH 4–7, Bio-Rad) were
rehydrated with 250 μl rehydration buffer (7 M urea, 2 M
thiourea, 4% (w/v) CHAPS, 2% (v/v) carrier ampholytes pH 3–10,
10 mM Tris, 43 mM DTT and 0.01% (v/v) bromophenol blue) for
16 h using a gel reswelling tray (GE Healthcare, Australia).
Depleted plasma samples (200 μg)weremixedwith rehydration
buffer to a final volume of 200 μl and incubated at room
temperature for 30 min with orbital mixing (1000 rpm), to
solubilise and denature the plasma proteins. For, IEF, each
sample was loaded onto the rehydrated IPG strips using sample
cups, which were placed at the acidic end of the strip. IEF was
then performed at room temperature for 120 kVh using the
IPGphor electrophoresis unit (GE Healthcare). After IEF, the IPG
strips were equilibrated (50 mM Tris–HCl pH 8.8, 6 M urea, 30%
(v/v) glycerol, 2% (w/v) SDS, 0.01% (v/v) bromophenol blue with
trace amounts of DTT) for 20 min on an orbital shaker at
low speed. Each of the IPG strips were laid on top of 4–20%
Criterion gels (Bio-Rad) and sealed using a 0.5% (w/v) agarose
sealing solution (Tris/Glycine/SDS buffer, 0.5% (w/v) agarose
and 0.01% (v/v) bromophenol blue) for electrophoresis in the
second dimension. Electrophoresis was performed on the
gel using the buffer system of Laemilli [18] at 100 V until
the bromophenol blue dye front migrated off the gel. After
electrophoresis, the proteins on the 2D gel were transferred on
to nitrocellulose membrane (GE Healthcare) by wet Western
transfer. ZAG protein was detected on the membrane with
rabbit polyclonal anti-ZAG antibody (Sigma-Aldrich, MO, USA);
using a working dilution of1:500 in an appropriate buffer.
2.7. ELISA quantitation of protein candidates
Sandwich enzyme-linked immuno sorbent assay (ELISA) kits
were used for the quantification of ZAG (Uscn Life Science
Inc. Wuhan, China), complement C3, C-reactive protein (CRP)
and Serum Amyloid A (SAA) (Genway Biotech Inc. CA).
Concentrations of ZAG and complement C3, proteins in the
plasma of TH-MYCN+/+ transgenic andWTmice as well as the
human plasma samples were determined according to the
manufacturer's protocol. In brief, mouse plasma samples
were diluted with dilution buffer, 1:1000 for ZAG and 1:50,000
for complement C3. Human plasma samples were diluted with
dilution buffer, 1:30 for ZAG and 1:50,000 for complement C3.Plasma concentration levels of CRP and SAA were determined
in the human samples using the aforementioned ELISA kits
and by diluting the samples 1:200 for CRP and 1:50 for SAA.
C3 protein extracted from mouse tissue was diluted at 1:500
and protein concentration was determined according to the
manufacturer's protocol.
2.8. Immunohistochemical analysis of TH-MYCN+/+ tissue
samples
Paraffin-embedded section of TH-MYCN+/+ tissue at 6 weeks of
age was harvested and fixed with formalin. Paraffin-embedded
sections were dried in a 60 °C oven for 1 h. The tissue slides
were then immersed in xylene to deparaffinise the section.
Slides were then re-hydrated with 100%, 90%, and 70% ethanol
sequentially. Antigen retrieval was done by immersing the
slides in 0.01 M tri-sodium citrate buffer with 0.05% Tween-20,
pH6, at 104 °C for 15 min. The endogenous peroxidases were
inactivated by immersing slides in 3% hydrogen peroxide. 10%
goat serumwas used to block non-specific binding of immuno-
globulin. The slideswere incubatedwith rabbit anti-ZAG (Sigma
Aldrich) at 1:150 dilution overnight at 4 °C. Rabbit IgG prepared
to the same concentration was used as negative control.
Secondary antibody used was goat anti-rabbit immunoglobu-
lin/biotinylated (Dako, E0432) at 1 in 500 dilution for 1 h, room
temperature. The biotinylated antibody was then labelled with
streptavidin-HRP (Dako,K1016) for 45 min at roomtemperature.
The sections were developed with 3, 3′-diaminobenzidine
tetrahydrochloride (Dako, K3468) and counterstained with
haematoxylin.
2.9. Bioinformatics, pathway analysis and
statistical analysis
For relative protein expression analysis, fold change was
calculated in TH-MYCN+/+ mice compared to WT littermates
and log2 transformed for normalisation. Unsupervised hierar-
chical cluster analysis was performed using Multi-Experiment
Viewer (MEV–TM4 microarray analysis software suite) to
generate evolutionary gene trees (Euclidean distance metric
selection and average linkage clustering parameters) [19]. To
identify functional protein groups and pathways the 86
candidate proteins were assessed using Gene Ontology (GO)
terms via the Memorial Sloan-Kettering Cancer Centre
database (http://cbio.mskcc.org/CancerGenes) and also the
Broad Institute Molecular Signatures database (MSigDB —
http://www.broadinstitute.org/ gsea/msigdb). Statistical sig-
nificance was evaluated using the Mann–Whitney, unpaired,
nonparametric t-test in GraphPad Prism 5 (p-values < 0.05
were considered statistically significant).3. Results
3.1. Identification and quantification of differentially
abundant plasma proteins from TH-MYCN+/+ and WT mice
The plasma collected from 10 TH-MYCN+/+ and 10 WT mice
at 2, 4 and 6 weeks of age was pooled and prefractionated
using the electrophoretic ProteomeSep device, to reduce the
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identification and quantification. Fig. 1A outlines the mass
spectrometry and label-free approach designed for identifica-
tion of differentially abundant candidate plasma proteins in
TH-MYCN+/+ and WT mice and generation of the final list of
candidate biomarkers for further analysis. Fig. 1B shows a
representation of the peptides identified by LC–MS/MS sepa-
rated by retention time and m/z. The datasets generated into
peak lists and analysed by Progenesis LC–MS/MS identified
> 200 proteins per size fraction and time-point to be differen-
tially abundant in the plasma of TH-MYCN+/+ and WT mice
(±5-fold relative peptide abundance and p < 0.05).
3.2. Profiling differentially abundant plasma proteins in
TH-MYCN+/+ and WT mice
To validate the label free LC–MS/MS method we selected zinc-
alpha2-glycoprotein (ZAG) as it displayed one of the highest
concentrations in the plasma of TH-MYCN+/+ mice compared
to controls at 6 weeks of age (408-fold higher concentration).
For 2DWestern immunoblot analysis, pooled plasma samples
from ten TH-MYCN+/+ and ten WT mice were analysed follow-
ing abundant plasma protein depletion. Three distinct iso-
forms of ZAG were detected in both the TH-MYCN+/+ and WTA
B
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the ZAG concentration range in the healthy individual
samples were in range of 120–276 pg/ml, where as some of
the neuroblastoma patient plasma samples exhibited a ZAG
plasma concentration of more than 760 pg/ml. All concentra-
tions were calculated using data extrapolated from a standardcurve. To investigate whether ZAG was expressed in the
neuroblastoma tumour, we performed immunohistochemical
(IHC) analysis on tissue samples obtained from TH-MYCN+/+
mice (Fig. 2F). Synthesis and secretion of ZAG has been
reported to occur in both the gastrointestinal (GI) tract as
well as the liver [21]. As indicated by the IHC staining of the
7J O U R N A L O F P R O T E O M I C S 9 6 ( 2 0 1 4 ) 1 – 1 2mouse tissue samples, the staining of ZAG can be observed in
both the GI tract and the liver. However, a much lower level
of ZAG expression could be detected in the neuroblastoma
tissue samples, compared with the GI tract and the liver. This
suggested that the greater abundance of ZAG in the plasma of
the TH-MYCN+/+mice is not directly secreted from the tumour,
but could be from another source that is affected by the
initiation or the progression of neuroblastoma. Further
studies will be required to determine the origin of ZAG in
TH-MYCN+/+ mice bearing neuroblastoma tumours.
3.3. Assessment of the top differentially abundant plasma
proteins in TH-MYCN+/+ and WT mice
From our initial analysis, we removed abundant proteins
including albumin, immunoglobulins, transferrin, alpha-1-
antitrypsin and haptoglobulin. The list was further refined to
include only proteins which were differentially expressed at
more than one time point to generate a final list of 86 can-
didates. The top candidates were clustered into 4 main groups
based on expression patterns over the time-course of the
experiment in TH-MYCN+/+ mice relative to WTmice (Fig. 3).
Two groups of proteins (group 2 and group 3) demonstrated
higher average expression in plasma from TH-MYCN+/+ mice
compared to WT mice at the early 2 week time-point during
tumour initiation. It is likely that these groups will contain
suitable biomarkers for early detection of neuroblastoma at
diagnosis or relapse. The average expression of group 1 by
contrastwashigher in TH-MYCN+/+mice at 4 weeks during early
tumour formation, and expression of group 4 was high at both
4 weeks and 6 weeks suggesting proteins associated with early
to advanced tumour formation. Interestingly, the majority of
proteins identified have not previously been associated with
neuroblastoma. We found a high proportion of proteins which
are secreted extracellularly (12 biomarkers from the 86 total
biomarkers), several of which are associated with other solid
tumour types such as Serpina6 (marker of resistance to therapy
in breast cancer — [22]) and FN1 (protects against apoptosis in
lung tumourigenesis— [23]).
Pathway analysiswas performed on the 86 candidate protein
set using MSigDB and the top 10 hits ranked on p-value are
shown in Fig. 4A. The top pathway identified involves protein
metabolism, specifically O-glycosylation, a post-translational
modificationwhich has known roles in the regulation of cellular
nutrient metabolism, protein stability and ligand presentation
for functional recognition [24]. Two additional pathways related
to glycosylation and metabolism were identified in the top 50
pathway hits (ranked #10 and #16), and four of the 5 proteins
in these data sets belonged to expression group 2 with high
expression in TH-MYCN+/+ mice at the early 2 week time-point
(Fig. 4B). The second ranked pathway to be identified involves
the complement and coagulation cascades, two linked proteo-
lytic cascades with roles in inflammation, immunosuppression,
and tumour development/metastasis [25]. A total of 5 protein
sets were identified in the top 50 pathways relevant to
the complement system, and 4 of the 5 proteins from our
analysis in these data sets clustered in group 4 with enhanced
abundance at 4 and 6 weeks in the TH-MYCN+/+ (Fig. 4C).
Interestingly, we found a total of 6 data sets related to liver
development, hepatoblastoma, or liver cancer in our top 50pathways (including two ranked within the top 10). These
datasets comprised a total of 23 of our candidate proteins, with
10 of these clustered in expression group 4 (shown in Fig. 4D).
The liver is a common site of metastasis for neuroblastoma [26],
however our finding could also suggest some overlaps in the
molecular mechanisms or the pathological processes of these
two cancer types.
3.4. Complement C3 protein is more abundant in plasma
samples from human neuroblastoma patients than healthy
volunteers
Complement C3 protein (C3) was significantly elevated in
TH-MYCN+/+ mice compared to WT counterparts at both 4 and
6 weeks of age (140-fold and 50-fold higher respectively). The
pathway analysis identified C3 as part of both the comple-
ment cascade and the liver cancer groups in our analysis
(Fig. 4), and as C3 levels are elevated in other cancer types
we chose to analyse it further in our mouse model and in
human plasma samples. The proteomics data was validated
using ELISA performed on pooled plasma from 10 mice of
each genotype per time-point, which confirmed significantly
higher C3 levels in TH-MYCN+/+ mice at both 4 and 6 weeks of
age (7-fold and 2-fold higher than in WT mice respectively,
Fig. 5A). The pattern of expression of C3 was similar to the
initial proteomics analysis, although the magnitude of differ-
ence in plasma protein concentration was reduced when
detected using ELISA. To determine whether elevated plasma
C3 was a consequence of higher C3 expression in tumour
tissues, ELISA was used to detect C3 levels in ganglia from WT
mice and in tumours from TH-MYCN+/+ mice. C3 protein was
significantly elevated in tumours from TH-MYCN+/+ mice com-
pared to WT counterparts at 6 weeks of age (Fig. 5B), however
no difference was observed at the earlier 4 week time-point.
Whilst this observation may reflect a reduced limit of detection
for C3 protein using ELISA, it could alternatively indicate that
accumulation of C3 in tumours is secondary to increased levels
in plasma.
To determine if these experimental observations would
translate to a similar finding inhumandisease, plasmasamples
obtained fromhealthy adults (N = 4) and newborns (N = 3)were
compared with plasma from 15 patients with neuroblastoma at
diagnosis for expression of C3 protein. The mean plasma level
of C3 in healthy individuals was 20 ng/ml (range: 8–37 ng/ml)
compared to 110 ng/ml (range: 73–176 ng/ml) in neuroblastoma
patients (median age 3.7 years) as determined by ELISA (Fig. 5C).
As C3 is an important component of the immune system, we
also assessed levels of two other inflammation-associated
proteins – acute phase response protein C-reactive protein
(CRP) and Serum Amyloid A (SAA) – to determine if C3 levels in
neuroblastoma plasma samples were non-specifically elevated
due to an inflammatory response. We did not observe sig-
nificant differences in plasma concentration of CRP or SAA
between healthy individuals and neuroblastoma patients using
ELISA (Supplementary Fig. 1), suggesting that elevated C3 may
potentially be a tumour-specific biomarker. Further validation
will be required in larger patient populations as well as age-
matched controls to confirm the validity of C3 as a plasma
biomarker of neuroblastoma. This study also demonstrates the
feasibility of using the TH-MYCN+/+ mouse model to identify
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Fig. 4 – Identification of functional groups of protein biomarkers using pathway analysis. (A) Top 10 significantly associated
pathways identified using MSigDB. Pathways were ranked by p-value (k/K indicates proportion of protein candidates which
overlap with the indicated data-set). (B–D) Expression patterns of individual proteins in TH-MYCN+/+ mice relative to WT
controls forming part of the top three pathways identified in part A.
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disease.4. Discussion
Initiation of neuroblastoma is executed by a series of molecular
events that is mediated by dysfunctional genes and proteins [1].
Postnatally persistent embryonal cells with tumorigenic capac-
ity possess the capacity to resist cell death imposed during the
final stages of neurodevelopment and undergo secondary
changes that characterize later tumour promotion and progres-
sion [27]. At 2 weeksof age,TH-MYCN+/+mice show the first signs
of neuroblastoma tumour initiation with the appearance of
neuroblast hyperplasia, which persists until tumour formation
and progression [7]. Studies have shown that this aberrant
survival is due to a diminished p53 response to conditions of
cellular stress, such as serumstarvation orwithdrawal of trophic
factor [28,29]. We hypothesised that identification of proteinsFig. 3 – Time-course expression patterns of 86 candidate protein
Relative expression of proteins was plotted at 2, 4 and 6 weeks of
groups of proteins with similar expression trends. The evolution
proteins within each of the 4 groups is shown on the right (grey
represent mean expression pattern for each group).differentially expressed at these early time-points, prior to
the onset of overt neuroblastoma, may be clinically useful as
indicators to predict the initiation and onset of neuroblastoma.
In this study, we employed a label-free approach based on a
comparison of peptide intensities, and quantitative analysis by
ion count, to assess differences in plasma protein con-
centrations from TH-MYCN+/+ and WT mice for the identifica-
tion of candidate plasma protein biomarkers of neuroblastoma.
This methodology has several advantages over traditional
proteomic analysis techniques utilising 2D polyacrylamide gel
electrophoresis (PAGE), including improved detection of low
mass and basic proteins and enhanced reproducibility [30].
Using a combination of the label-free proteomics approach
and a transgenic MYCN mouse model of neuroblastoma, we
identified a list of 86 candidate protein biomarkers present in
plasma with altered levels compared to WT mice. A total of 27
proteins from the candidate list were significantly higher in
plasma of the TH-MYCN+/+ mice than in WT littermates at
the early 2 week time-point, and 49 were higher at the 4 weekbiomarkers in TH-MYCN+/+ mice relative to WT controls.
age and hierarchical cluster analysis performed to generate 4
ary tree is depicted on the left, and expression patterns of
lines represent expression of individual proteins, black lines
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Fig. 5 – Plasma concentration levels of complement C3 in the
TH-MYCN+/+ mouse model and in human neuroblastoma
patient plasma samples. (A) ELISA assays demonstrate a
significant difference in the concentration of complement C3
in the pooled plasma of 4 week old TH-MYCN+/+ and WT
mice. Asterisks (***) represent p-value < 0.001. (B) Proteins
extracted from the neuroblastoma tumour and ganglia tissue
from 4 and 6 week old TH-MYCN+/+ (N = 4/genotype/
time-point) and WT mice were analysed with a complement
C3 ELISA. Asterisk (*) represents p-value < 0.05. (C) ELISA
assays were performed to detect C3 protein levels of plasma
in a cohort of human neuroblastoma plasma samples
(N = 15) and in plasma from healthy individuals (N = 3 from
cord blood and N = 4 from peripheral blood). Asterisks (****)
represent p-value < 0.0001.
10 J O U R N A L O F P R O T E O M I C S 9 6 ( 2 0 1 4 ) 1 – 1 2time-point, suggesting that these candidates should be consid-
ered as markers for early detection of neuroblastoma.
Cluster and pathway analyses identified a group of
proteins involved in post-translational protein modification,
specifically glycosylation, which demonstrated significantly
higher expression in TH-MYCN+/+ mice at 2 weeks of age
before steadily declining during disease progression. Aberra-
tions in the glycosylation of proteins have been associated
with almost all forms of human cancers [31]. Studies have also
suggested that aberrations in protein glycosylation can result
in the initiation of oncogenesis, or that oncogenic transfor-
mation can cause alterations in protein glycosylation [31].
Other studies have shown similarities in the glycosylation
pattern of proteins in different human neuroblastoma. The
glycopeptides extracted from neuroblastoma tumours exhib-
ited a low percentage of fucose-containing glycosylation [32].
Thus, it appears that the potential biomarkers identified by
our cluster and pathway analysis may have significant roles
in neuroblastoma biology. Albeit, further functional studies of
each candidate will be required to confirm this hypothesis.
Pathway analysis also identified the complement system
as being significantly associated with our candidate protein
list. From this data, C3 was further characterised as a plasma
biomarker candidate for neuroblastoma in the TH-MYCN+/+
murine model and in primary human plasma samples from
neuroblastoma patients. Activation of C3 is central to the
three complement pathways, which collectively result in the
inflammatory response and the elimination of self- and
non-self-antigenic targets [33]. However, using assays that
detect CRP and SAA plasma levels we have shown that
elevated C3 levels are not due acute phase responses and are
most likely linked to neuroblastoma tumour formation. C3 is
elevated in sera from pancreatic adenocarcinoma patients
compared to normal individuals [34], and high levels are also
observed in serum from breast, colorectal and lung cancer
patients [30]. According to The Royal College of Pathologists
of Australasia manual, the normal range of C3 in human
plasma is recorded to be 0.9–1.8 g/l. Complement proteins
have a central role in innate immunity, where they destroy
antibody-coated targets such as apoptotic cells [35]. Deregu-
lation of these molecules has also been associated with
autoimmune and non-immune diseases [36,37]. In the context
of carcinogenesis, the complement C3 protein has been
implicated in the production of VEGF and extracellular matrix
reorganisation and disintegration which contributes to the
tumourigenic hallmarks of angiogenesis, invasion and migra-
tion, respectively [38].
Complement C4-B and complement factor D, which are
other members of the complement family were identified by
ion count to be more abundant in the plasma of TH-MYCN+/+
compared to the WT mice at 4 and 6 weeks of age. Therefore,
it is possible that as an immune response to the initiation and
development of neuroblastoma, several members of the
complement protein family have been found to be more
abundant in the plasma of TH-MYCN+/+ mice, compared to
their WT counterparts. It also should be noted that a recent
study has suggested that complement protein members C3,
C4 and C5a may aid tumour growth by a mechanism of
immunosuppression [38,39]. Thus, the abundance of these
complement proteins in the plasma of the TH-MYCN+/+ mice
11J O U R N A L O F P R O T E O M I C S 9 6 ( 2 0 1 4 ) 1 – 1 2may either be a marker of the immune response to the cancer
or aid in the development and growth of neuroblastoma.5. Conclusions
Early detection and disease recurrence monitoring are critical
areas in cancer treatment in which specific biomarker panels
are likely to be very important in these key areas. The MYCN
transgene of the mouse model used in our studies accurately
reflects the more clinically aggressive forms of neuroblasto-
ma. The validity of our data is strengthened by the finding
that ZAG and C3, chosen for validation, have been previously
published as serum markers in cancer. Further characterisa-
tion of the candidate biomarkers in our neuroblastoma
animal model, and in human plasma patient samples, will
likely result in a panel of biomarkers, that could be utilised
for early detection and prediction of relapse risk in childhood
neuroblastoma.
Supplementary data to this article can be found online at
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